Akademik Veri Yönetim Sistemi
Retina-Vitreus, cilt.24, sa.4, ss.309-312, 2016 (Scopus)
© 2016 Gazi Eye Foundation. All rights reserved.Purpose: To evaluate the effect of intraretinal foveal cyst size prior to the treatment on the response of treatment and visual prognosis in patients treated with intravitreal ranibizumab for diabetic macular edema (DME). Materials and Methods: One hundred seventy-five eyes of 115 patients diagnosed as DME in our retina clinic between April 2009-June 2014 were included. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) of the patients were recorded before and after the treatment of intravitreal ranibizumab. The patients were classified into 3 groups according to the foveal cyst sizes on the baseline spectral-domain optical coherence tomography (SD-OCT) findings (Group 1;≤ 300 μm, Group 2; 300-600 μm, Group 3; ≥ 600 μm). Results: The mean age of the patients was 60.24±8.49 (36-81) years and the mean of follow-up time was 22.64 ± 12.03 (4-50) months. The number of enjections administered to the groups was similar (p > 0.05). A significant improvement in visual acuity was provided in all 3 groups treated with ranibizumab. There wasn't any significant difference in BCVA between the groups in both baseline and final examinations. A significant reduction in CMT with ranibizumab treatment was found in all 3 groups. There was significant difference between the groups before the treatment, but there wasn't after ranibizumab treatment. There was no correlation between BCVA and the cyst size (r=0.138, p=0.196) and CMT (r=0.102, p=0.115). Conclusion: It was found that the cyst size is not the only prognostic factor in the response to ranibizumab treatment with respect to visual acuity and macular thickness in DME.